Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma

Journal of Cellular Biochemistry

Volumn 103, Issue 3, 2008, Pages 740-752

  He, Qing Yu ^a,b   Zhu, Rui ^a   Lei, Ting ^a,c   Ng, Mandy Y M ^a   Luk, John M ^a   Sham, Pak ^a   Lau, George K K ^a   Chiu, Jen Fu ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b JINAN UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

2DE; HBV; HCC; MALDI TOF MS; Protein profiling; SELDI TOF ProteinChip; Serum markers; Tumor biomarkers

Indexed keywords

ACETONITRILE; BIOLOGICAL MARKER;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B VIRUS; HUMAN; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

HEPATITIS B VIRUS;

EID: 39049137614     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21443     Document Type: Article

References (36)

1. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, Dwek RA, Mattu TS, Mehta AS. 2005. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 102:779-784.
2. Chernokalskaya E, Gutierrez S, Pitt AM, Leonard JT. 2004. Ultrafiltration for proteomic sample preparation. Electrophoresis 25:2461-2468.
3. Comunale MA, Mattu TS, Lowman MA, Evans AA, London WT, Semmes OJ, Ward M, Drake R, Romano PR, Steel LF, Block TM, Mehta A. 2004. Comparative proteomic analysis of de-N-glycosylated serum from hepatitis B carriers reveals polypeptides that correlate with disease status. Proteomics 4:826-838.
4. Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, Fang CY, Lu HJ, Yang PY, Tang ZY. 2005. Heat-shock protein 27: A potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics 5:4581-4588.
5. Greenough C, Jenkins RE, Kitteringham NR, Pirmohamed M, Park BK, Pennington SR. 2004. A method for the rapid depletion of albumin and immunoglobulin from human plasma. Proteomics 4:3107-3111.
6. Harper RG, Workman SR, Schuetzner S, Timperman AT, Sutton JN. 2004. Low-molecular-weight human serum proteome using ultrafiltration, isoelectric focusing, and mass spectrometry. Electrophoresis 25:1299-1306.
7. He QY, Chiu JF. 2003. Proteomics in biomarker discovery and drug development. J Cell Biochem 89:868-886.
8. He QY, Lau GK, Zhou Y, Yuen ST, Lin MC, Kung HF, Chiu JF. 2003. Serum biomarkers of hepatitis B virus infected liver inflammation: A proteomic study. Proteomics 3:666-674.
9. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. 2004. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics 4:3276-3287.
10. He QY, Zhu R, Ren Y, Tam PK, Chiu JF. 2005. Serological protein profiling of neuroblastoma by ProteinChip SELDI-TOF technology. J Cell Biochem 95:165-172.
11. Johnson PJ. 1999. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 14(Suppl):S32-S36.
12. Johnson PJ. 2001. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5:145-159.
13. Kawakami T, Hoshida Y, Kanai F, Tanaka Y, Tateishi K, Ikenoue T, Obi S, Sato S, Teratani T, Shiina S, Kawabe T, Suzuki T, Hatano N, Taniguchi H, Omata M. 2005. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics 5:4287-4295.
14. Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM, Beretta L. 2002. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 1:197-203.
15. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Yu CY, Lu FJ, Chow LP. 2005. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 4:2062-2069.
16. Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, Yu CY, Wen CL, Lu FJ, Chow LP. 2006. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 6:2865-2873.
17. Li C, Hong Y, Tan YX, Zhou H, Ai JH, Li SJ, Zhang L, Xia QC, Wu JR, Wang HY, Zeng R. 2004. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol Cell Proteomics 3:399-409.
18. Li C, Tan YX, Zhou H, Ding SJ, Li SJ, Ma DJ, Man XB, Hong Y, Zhang L, Li L, Xia QC, Wu JR, Wang HY, Zeng R. 2005. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: Identification of potential tumor markers. Proteomics 5:1125-1139.
19. Luk JM, Lam CT, Siu AF, Lam BY, Ng IO, Hu MY, Che CM, Fan ST. 2006. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 6:1049-1057.
20. Melle C, Kaufmann R, Hommann M, Bleul A, Driesch D, Ernst G, von Eggeling F. 2004. Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int J Oncol 24:885-891.
21. Merrell K, Southwick K, Graves SW, Esplin MS, Lewis NE, Thulin CD. 2004. Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech 15:238-248.
22. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, Janeau JL, Bezeaud A, Delforge D, Cubizolles M, Laurendeau I, Bedossa P. 2005. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41:40-47.
23. Peng X, Wu Y, Chen J, Wang S. 2004. Proteomic approach to identify acute phase response-related proteins with low molecular weight in loach skin following injury. Proteomics 4:3989-3997.
24. Petricoin EF, Liotta LA. 2003. Clinical applications of proteomics. J Nutr 133:2476S-2484S.
25. Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, Lee CC, Leung TW, Ho SK, Johnson PJ. 2003. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49:752-760.
26. Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, Sung JJ. 2005. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection qy serum proteomic fingerprinting: A pilot study. Clin Chem 51:328-335.
27. Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR. 2005. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 41:634-642.
28. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Toda T, Sakaida I, Okita K, Oka M, Nakamura K. 2003. Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics 3:2487-2493.
29. Takashima M, Kuramitsu Y, Yokoyama Y, Iizuka N, Fujimoto M, Nishisaka T, Okita K, Oka M, Nakamura K. 2005. Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: Association with tumor progression as determined by proteomic analysis. Proteomics 5:1686-1692.
30. Tan TL, Chen WN. 2005. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: Potential in identification of early diagnostic markers for HCC. J Clin Virol 33:293-298.
31. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. 2003. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2:1096-1103.
32. Uhlar CM, Whitehead AS. 1999. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265:501-523.
33. Xu XQ, Leow CK, Lu X, Zhang X, Liu JS, Wong WH, Asperger A, Deininger S, Eastwood Leung HC. 2004. Molecular classification of liver cirrhosis in a rat model by proteomics and bioinformatics. Proteomics 4:3235-3245.
34. Zhang N, Ahsan MH, Purchio AF, West DB. 2005. Serum amyloid A-luciferase transgenic mice: Response to sepsis, acute arthritis, and contact hypersensitivity and the effects of proteasome inhibition. J Immunol 174:8125-8134.
35. Zhu H, Bilgin M, Snyder M. 2003. Proteomics Annu Rev Biochem 72:783-812.
36. Zhu XD, Zhang WH, Li CL, Xu Y, Liang WJ, Tien P. 2004. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. World J Gastroenterol 10:2327-2329.